Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 8/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LPL | P06858 | 2/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.33 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17221770 | 0.81 | MGLL (0.41) | MGLLENPP2LPLLIPGCA1 | |
| SCHEMBL840219 | 0.73 | MGLL (0.64) | MGLLENPP2KDM4EALDH1A1LPL | |
| SCHEMBL1814249 | 0.71 | MGLL (0.62) | MGLLENPP2KDM4EALDH1A1LPL | |
| SCHEMBL22130545 | 0.70 | MGLL (0.56) | MGLLENPP2KDM4EALDH1A1LPL | |
| SCHEMBL2030291 | 0.70 | MGLL (0.71) | MGLLENPP2KDM4EALDH1A1LPL | |
| SCHEMBL16307074 | 0.67 | MGLL (0.56) | MGLLENPP2KDM4EALDH1A1LPL | |
| SCHEMBL19663724 | 0.67 | MGLL (0.56) | MGLLENPP2KDM4EALDH1A1LPL | |
| SCHEMBL9911114 | 0.66 | MGLL (0.55) | MGLLENPP2KDM4EALDH1A1LPL | |
| SCHEMBL2568889 | 0.66 | MGLL (0.55) | MGLLENPP2KDM4EALDH1A1CYP26B1 | |
| SCHEMBL30864983 | 0.66 | MGLL (0.55) | MGLLENPP2KDM4EALDH1A1LPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-7838533-B2 | Azaindole inhibitors of MTP and ApoB | MERCK PATENT GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| US-20090036481-A1 | Novel Azaindole Inhibitors of Mtp and Apob | MERCK PATENT GMBH (DE) | 2009-02-05 | — | — | US | disclosed |
| EP-1771446-B1 | AZAINDOLE INHIBITORS OF MTP AND APOB | MERCK PATENT GMBH (DE) | 2008-06-11 | — | — | EP | disclosed |
| EP-1771446-A2 | AZAINDOLE INHIBITORS OF MTP AND APOB | Merck Patent GmbH (DE) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006010423-A2 | AZAINDOLE INHIBITORS OF MTP AND APOB | MERCK PATENT GMBH (DE) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036481-A1 | Novel Azaindole Inhibitors of Mtp and Apob | APOB, MTPN, HDLBP | MGLL 70/4885ENPP2 1116/4885KDM4E 3429/4885 |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | MGLL 2486/4885ENPP2 147/4885KDM4E 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.